Plus Therapeutics Reports First Patient Dosing in P-I/IIa (ReSPECT-LM) Dose Escalation Trial of 186RNL for Leptomeningeal Metastases
Shots:
- The first patient has been dosed in the P-I/IIa (ReSPECT-LM) dose-escalation trial to evaluate the MTD, MFD, safety & efficacy of Rhenium-186 NanoLiposome via IVC in patients with LM, following standard surgical, radiation & CT treatment
- The 1EPs of the study is the incidence and severity of AEs/serious AEs & DLTs while 2EPs include ORR, DoR, PFS & OS
- In preclinical studies, the therapy showed no significant toxicity & treatment led to a reduction in tumor burden in two animal models of LM. 186RNL has received the FTD from the US FDA for the treatment of LM & is also being evaluated in two US clinical trials for CNS cancers
Ref: Plus Therapeutics | Image: Plus Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
